| Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data (NCT06754865) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2024-12-01 |
| Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (NCT06574503) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2024-12-01 |
| Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications (NCT06573008) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2024-11-11 |
| Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (NCT06643156) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2024-09-27 |
| Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (NCT06678542) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2024-09-27 |
| GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (NCT05814926) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2023-04-26 |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (NCT05789342) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2023-02-15 |
| To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (NCT05474755) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2022-07-28 |
| A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers (NCT05103241) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-10-26 |
| Efficacy and Safety of Intramuscular Injection of Xiyanping Injection in the Treatment of Acute Bronchitis in Children (NCT04926506) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-10-08 |
| A Phase I Study of BR790 in Subjects With Advanced Solid Tumors (NCT04891653) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-06-30 |
| Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy (NCT07563634) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-02-07 |
| A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy (NCT04737837) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-01-31 |
| A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza (NCT04736758) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-01-08 |
| Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (NCT04556539) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-12-15 |
| SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (NCT04486937) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-08-30 |
| Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects (NCT04729764) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-08-27 |
| A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients (NCT04556292) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-08-12 |
| Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia (NCT04296383) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-06-15 |
| Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia (NCT04275388) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-05-15 |
| Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) (NCT04295551) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2020-03-14 |
| Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children (NCT04158310) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2019-11-11 |
| Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients (NCT03971383) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2019-06-10 |
| Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms (NCT03947411) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2019-03-04 |
| Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers (NCT03641794) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2018-09-07 |
| Study of Aolanti Weikang Tablets in Healthy Volunteers (NCT03358485) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2017-12-14 |